Rubenstein Law Partner, Miriam Fresco Agrait, Appointed To Plaintiffs' Leadership In The Depo-Provera Litigation

2025-03-21 05:45:43

(MENAFN- PR Newswire) Mrs. Agrait brings extensive experience in mass torts and product liability cases, making her an invaluable addition to the subcommittee. In this role, she will assist in overseeing the management and organization of critical data, ensuring the integrity and accessibility of vital case information.

"We are incredibly proud of Miriam's appointment to this subcommittee," said Nicole Rubenstein Armstrong, CEO of Rubenstein Law. "Her dedication, experience, and expertise will undoubtedly contribute to the fair and efficient administration of this litigation."

The Depo-Provera litigation arises from claims that prolonged use of Depo-Provera significantly increases the risk of developing meningioma, a serious type of brain tumor. Plaintiffs claim that the manufacturer failed to adequately warn users about this potential health hazard.

Mrs. Agrait's appointment further solidifies Rubenstein Law's reputation as a leader in mass tort and pharmaceutical litigation. The firm remains committed to advocating for those affected by corporate negligence and ensuring justice prevails.

For media inquiries or further information, please contact:

Katie Amor
Chief Creative Officer
Rubenstein Law
786-230-2017
[email protected]

SOURCE Rubenstein Law

MENAFN21032025003732001241ID1109343273

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.